CanadaBis Capital Past Earnings Performance
Past criteria checks 2/6
CanadaBis Capital has been growing earnings at an average annual rate of 73%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 44.4% per year. CanadaBis Capital's return on equity is 7.4%, and it has net margins of 3.3%.
Key information
73.0%
Earnings growth rate
75.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 44.4% |
| Return on equity | 7.4% |
| Net Margin | 3.3% |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
Recent updates
CanadaBis Capital Inc. (CVE:CANB) Not Doing Enough For Some Investors As Its Shares Slump 33%
Dec 03
Why Investors Shouldn't Be Surprised By CanadaBis Capital Inc.'s (CVE:CANB) Low P/E
Oct 13We Think CanadaBis Capital (CVE:CANB) Is Taking Some Risk With Its Debt
Aug 19Why Investors Shouldn't Be Surprised By CanadaBis Capital Inc.'s (CVE:CANB) 29% Share Price Plunge
Jul 14CanadaBis Capital (CVE:CANB) Has A Pretty Healthy Balance Sheet
May 09Earnings Working Against CanadaBis Capital Inc.'s (CVE:CANB) Share Price Following 48% Dive
Apr 02If EPS Growth Is Important To You, CanadaBis Capital (CVE:CANB) Presents An Opportunity
Feb 12Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Dec 01CanadaBis Capital (CVE:CANB) Seems To Use Debt Quite Sensibly
Jul 17CanadaBis Capital Inc.'s (CVE:CANB) Shares Climb 70% But Its Business Is Yet to Catch Up
Apr 17Auditors Have Doubts About CanadaBis Capital (CVE:CANB)
Dec 01Is CanadaBis Capital (CVE:CANB) A Risky Investment?
Aug 13Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Apr 30Is CanadaBis Capital (CVE:CANB) Using Debt Sensibly?
Jan 13Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Apr 07Have Insiders Been Selling CanadaBis Capital Inc. (CVE:CANB) Shares This Year?
Feb 14Here's Why CanadaBis Capital (CVE:CANB) Can Afford Some Debt
Dec 23
Revenue & Expenses Breakdown
How CanadaBis Capital makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 18 | 1 | 7 | 0 |
| 30 Apr 24 | 19 | 2 | 7 | 0 |
| 31 Jan 24 | 21 | 3 | 7 | 0 |
| 31 Oct 23 | 23 | 4 | 7 | 0 |
| 31 Jul 23 | 22 | 4 | 7 | 0 |
| 30 Apr 23 | 22 | 4 | 6 | 0 |
| 31 Jan 23 | 18 | 3 | 5 | 0 |
| 31 Oct 22 | 15 | 2 | 5 | 0 |
| 31 Jul 22 | 12 | 1 | 4 | 0 |
| 30 Apr 22 | 9 | -1 | 5 | 0 |
| 31 Jan 22 | 8 | -1 | 5 | 0 |
| 31 Oct 21 | 8 | -2 | 5 | 0 |
| 31 Jul 21 | 7 | -3 | 4 | 0 |
| 30 Apr 21 | 9 | -2 | 4 | 0 |
| 31 Jan 21 | 7 | -2 | 4 | 0 |
| 31 Oct 20 | 6 | -3 | 4 | 0 |
| 31 Jul 20 | 4 | -5 | 6 | 0 |
| 30 Apr 20 | 1 | -10 | 8 | 0 |
| 31 Jan 20 | 0 | -13 | 8 | 0 |
| 31 Oct 19 | 0 | -12 | 7 | 0 |
| 31 Jul 19 | 0 | -9 | 5 | 0 |
| 30 Apr 19 | 0 | -5 | 1 | 0 |
| 31 Jan 19 | 0 | -1 | 1 | 0 |
| 31 Oct 18 | 0 | 0 | 0 | 0 |
| 31 Jul 18 | 0 | 0 | 0 | 0 |
Quality Earnings: CANB has high quality earnings.
Growing Profit Margin: CANB's current net profit margins (3.3%) are lower than last year (20%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CANB has become profitable over the past 5 years, growing earnings by 73% per year.
Accelerating Growth: CANB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CANB had negative earnings growth (-86.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-51.1%).
Return on Equity
High ROE: CANB's Return on Equity (7.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 07:50 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CanadaBis Capital Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|